1. Home
  2. AIM
  3. AIM News

Latest AIM ImmunoTech Inc. (AIM) News on November 18, 2024

AIM ImmunoTech Inc (AIM) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
AIM

GuruFocus.com

2 days ago

AIM ImmunoTech Inc (AIM) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update
AIM

GlobeNewswire

3 days ago

AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update

AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast
AIM

GlobeNewswire

12 days ago

AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast

AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders
AIM

Business Wire

14 days ago

AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders

AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC
AIM

GlobeNewswire

a month ago

AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC

AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis
AIM

GlobeNewswire

a month ago

AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis

AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering
AIM

GlobeNewswire

2 months ago

AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering

AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
AIM

GlobeNewswire

2 months ago

AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
AIM

GlobeNewswire

2 months ago

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue
AIM

GlobeNewswire

2 months ago

AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue

AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
AIM

GlobeNewswire

3 months ago

AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
AIM

GlobeNewswire

3 months ago

AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update

AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast
AIM

GlobeNewswire

3 months ago

AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast

AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM

GlobeNewswire

4 months ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
AIM

GlobeNewswire

4 months ago

AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy

AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM

GlobeNewswire

4 months ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
AIM

GlobeNewswire

5 months ago

AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference

Better AI Stock: Palantir vs. Snowflake
AIM

Motley Fool

5 months ago

Better AI Stock: Palantir vs. Snowflake

Is Now the Time to Buy 3 of the S&P 500's Highest-Yielding Dividend Stocks?
AIM

Motley Fool

5 months ago

Is Now the Time to Buy 3 of the S&P 500's Highest-Yielding Dividend Stocks?

BigBear.ai Stock: Buy, Sell, or Hold?
AIM

Motley Fool

5 months ago

BigBear.ai Stock: Buy, Sell, or Hold?

Indonesia's first Olympic gymnast encourages others to 'dream higher'
AIM

AFP

5 months ago

Indonesia's first Olympic gymnast encourages others to 'dream higher'

Where Will CrowdStrike Stock Be in 1 Year?
AIM

Motley Fool

5 months ago

Where Will CrowdStrike Stock Be in 1 Year?

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp
AIM

GuruFocus.com

5 months ago

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp

Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...
AIM

GuruFocus.com

5 months ago

Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...

A Look At The Intrinsic Value Of Deufol SE (HMSE:DE1)
AIM

Simply Wall St.

5 months ago

A Look At The Intrinsic Value Of Deufol SE (HMSE:DE1)

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
AIM

GlobeNewswire

5 months ago

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series

AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering
AIM

GlobeNewswire

6 months ago

AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering

AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
AIM

GlobeNewswire

6 months ago

AIM ImmunoTech to Participate in Two Upcoming Investor Conferences

AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update
AIM

GlobeNewswire

6 months ago

AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update

AIM

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/15/2024

AIM

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/13/2024

AIM

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/10/2024

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
AIM

GlobeNewswire

6 months ago

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
AIM

GlobeNewswire

6 months ago

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
AIM

GlobeNewswire

7 months ago

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM

GlobeNewswire

7 months ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM

GlobeNewswire

7 months ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
AIM

GlobeNewswire

7 months ago

AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs

AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM

GlobeNewswire

7 months ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
AIM

GlobeNewswire

7 months ago

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
AIM

GlobeNewswire

8 months ago

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
AIM

GlobeNewswire

8 months ago

AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
AIM

GlobeNewswire

8 months ago

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
AIM

GlobeNewswire

8 months ago

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM

GlobeNewswire

8 months ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM

GlobeNewswire

8 months ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
AIM

GlobeNewswire

8 months ago

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity

AIM ImmunoTech Announces Launch of CEO Corner Platform
AIM

GlobeNewswire

8 months ago

AIM ImmunoTech Announces Launch of CEO Corner Platform

AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
AIM

GlobeNewswire

9 months ago

AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update

AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
AIM

GlobeNewswire

9 months ago

AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer

AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
AIM

GlobeNewswire

9 months ago

AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

Farmer Brothers to report fiscal second quarter 2024 financial results
AIM

GlobeNewswire

10 months ago

Farmer Brothers to report fiscal second quarter 2024 financial results

AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
AIM

GlobeNewswire

10 months ago

AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer

AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer
AIM

GlobeNewswire

10 months ago

AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer

Zacks.com featured highlights Universal Stainless & Alloy, Lakeland, NGL Energy and Iovance
AIM

Zacks

10 months ago

Zacks.com featured highlights Universal Stainless & Alloy, Lakeland, NGL Energy and Iovance

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
AIM

GlobeNewswire

10 months ago

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

AIM

Business Wire

10 months ago

AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting

Kellner Seeking Expedited Appeal of Delaware Court Finding that Nomination Notice was Properly Denied
AIM

PR Newswire

10 months ago

Kellner Seeking Expedited Appeal of Delaware Court Finding that Nomination Notice was Properly Denied

H World Group Limited Announces the Change of Officers
AIM

GlobeNewswire

a year ago

H World Group Limited Announces the Change of Officers

AIM

Business Wire

a year ago

Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board’s Determination that Activist Group’s Nominations Are Invalid

AIM

GlobeNewswire

a year ago

The Herzfeld Caribbean Basin Fund, Inc. Quarterly Distribution in Stock and Cash

AIM

GlobeNewswire

a year ago

The Herzfeld Caribbean Basin Fund, Inc. Announces Final Results of Rights Offering

AIM

GlobeNewswire

a year ago

The Herzfeld Caribbean Basin Fund, Inc. Announces Preliminary Results of Rights Offering

AIM

Business Wire

a year ago

AIM ImmunoTech Provides Update Regarding Annual Meeting

Edgio Announces Availability of CMCD Reports
AIM

Business Wire

a year ago

Edgio Announces Availability of CMCD Reports

AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
AIM

GlobeNewswire

a year ago

AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents

AIM

GlobeNewswire

a year ago

The Herzfeld Caribbean Basin Fund, Inc. Extends Expiration Date of Non-Transferable Rights Offering; Reinstates Quarterly Distribution; Revises Self-Tender Policy; Extends Management Fee Waiver; and Reports Results of Annual Stockholder Meeting

7 Small-Cap Stocks Set to Soar as Interest Rates Stabilize
AIM

InvestorPlace

a year ago

7 Small-Cap Stocks Set to Soar as Interest Rates Stabilize

UroGen Pharma Ltd (URGN) Reports Growth in Q3 Revenue and Progress in Clinical Trials
AIM

GuruFocus.com

a year ago

UroGen Pharma Ltd (URGN) Reports Growth in Q3 Revenue and Progress in Clinical Trials

InspireMD, Inc. (NASDAQ:NSPR) Q3 2023 Earnings Call Transcript
AIM

Insider Monkey

a year ago

InspireMD, Inc. (NASDAQ:NSPR) Q3 2023 Earnings Call Transcript

AIM

GlobeNewswire

a year ago

CORRECTION - The Herzfeld Caribbean Basin Fund, Inc. Announces Estimated Subscription Price for Rights Offering

AIM

GlobeNewswire

a year ago

The Herzfeld Caribbean Basin Fund, Inc. Announces Estimated Subscription Price for Rights Offering

Share on Social Networks: